ADC Therapeutics SA ADCT.N, ADCT.K is expected to show a rise in quarterly revenue when it reports results on March 10 for the period ending December 31 2025
The Epalinges Vaud-based company is expected to report a 26.5% increase in revenue to $21.39 million from $16.91 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for ADC Therapeutics SA is for a loss of 27 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for ADC Therapeutics SA is $8.00, about 90.9% above its last closing price of $4.19
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.36 | -0.36 | -0.30 | Beat | 17.1 |
Jun. 30 2025 | -0.48 | -0.47 | -0.38 | Beat | 19.8 |
Mar. 31 2025 | -0.39 | -0.40 | -0.36 | Beat | 10.7 |
Dec. 31 2024 | -0.44 | -0.41 | -0.29 | Beat | 29.6 |
Sep. 30 2024 | -0.36 | -0.39 | -0.42 | Missed | -6.3 |
Jun. 30 2024 | -0.45 | -0.46 | -0.38 | Beat | 16.9 |
Mar. 31 2024 | -0.55 | -0.56 | -0.56 | Met | -0.8 |
Dec. 31 2023 | -0.48 | -0.50 | -1.03 | Missed | -104.8 |
This summary was machine generated March 6 at 12:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)